Compare YieldMax AI & Tech Portfolio Option Income ETF (GPTY) vs Iovance Biotherapeutics Inc. Common Stock (IOVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax AI & Tech Portfolio Option Income ETF vs Iovance Biotherapeutics Inc. Common Stock — how do they compare? YieldMax AI & Tech Portfolio Option Income ETF trades at $42.65 (market cap $135.69M), while Iovance Biotherapeutics Inc. Common Stock trades at $14.57 (market cap $6.04B). The key difference: Iovance Biotherapeutics Inc. Common Stock is far larger — about 44.5× YieldMax AI & Tech Portfolio Option Income ETF's market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, YieldMax AI & Tech Portfolio Option Income ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax AI & Tech Portfolio Option Income ETF for 60 Days and Iovance Biotherapeutics Inc. Common Stock for 0 Days on average.
| GPTY | IOVA | |
|---|---|---|
Market Cap | $135.69M | $6.04B |
Volume | 97,442 | 14,805,993 |
Sector | Income / Options Overlay | Health |
52-Week High | $50.52 | $14.82 |
52-Week Low | $34.73 | $1.81 |
Typical Hold Time | 60 Days | 0 Days |
Enterprise Value | — | $5.97B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About YieldMax AI & Tech Portfolio Option Income ETF
GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.
Read more on GPTY →About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →
